What Actually Happens When You Run a Zoetis Dx Test in a Busy Clinic
I still remember the first time we ran a panel on a dog with chronic gastrointestinal symptoms that every other test had come back normal on. The PCR result lit up for Giardia, Clostridium, and a couple of other things most labs don't even bother screening for. It changed the treatment plan entirely. That is basically what Zoetis Dx does. It moves veterinary diagnostics away from the old culture-and-wait approach and into molecular testing that gives you answers the same day instead of days later. The core idea is straightforward. Zoetis Dx leverages PCR-based technology to detect specific genetic material from pathogens in samples. Instead of waiting for bacteria to grow on a plate, which can take 24 to 72 hours and sometimes never happens at all, you run the sample through a molecular assay and get results in a couple of hours. The platform covers respiratory panels, gastrointestinal panels, tick-borne diseases, and a few other categories depending on the region and the specific test version. Here is the thing most people miss when they look at these tests for the first time. Molecular diagnostics do not tell you if the organism is causing the disease. They tell you if the genetic material is present. That distinction matters. I had a case where a cat tested positive for FELV via PCR but was completely asymptomatic. The viral load was low. It turned out the cat was just a persistent carrier from an earlier infection, not actively ill. If you treat based solely on the positive result without looking at the whole clinical picture, you end up chasing ghosts. Always correlate with clinical signs and, when possible, run a confirmatory test like an antigen test or an PCR with a quantitative readout.
The workflow itself is not complicated. You collect the sample using the right swab or stool container, mix it into the provided lysis buffer, load it onto the instrument, and wait. Zoetis Dx instruments are generally benchtop and run one sample at a time or in small batches. Turnaround is typically two to three hours from sample to result. Results come back as positive, negative, or invalid. There is no gray area in the output, which is both a strength and a limitation. An invalid result usually means the internal control failed, and you need to pull another sample and retest. Do not just guess and repeat the same sample. Pull a fresh one. Contamination at the collection step ruins more tests than anything else. One practical issue I ran into involves fecal samples from dogs with hemorrhagic diarrhea. The old instinct was to just smear a bit onto a slide or throw it in a bag and send it off. With Zoetis Dx, you need a proper fecal integrity profile. If the sample has blood, mucus, or excessive water content, the PCR inhibitors can interfere with amplification. I learned this the hard way when three consecutive tests on the same stool came back invalid. The workaround was simple but obvious only after the fact. I diluted the sample with the provided phosphate-buffered saline and ran a second dilution too. The 1 in 10 dilution gave a clean result. Inhibitors get diluted out while the target DNA stays detectable. Write that down somewhere if you do a lot of stool PCR work. It will save you a lot of wasted reagents. Respiratory panels are probably the most commonly used tests in companion animal practice right now. Kennel cough outbreaks, unresponsive pneumonias, chronic coughs that refuse to respond to the usual antibiotics. You swab the nasopharynx, run the panel, and within a few hours you know whether you are dealing with Bordetella, Canine Influenza, Canine Respiratory Coronavirus, or something else entirely. The value here is not just speed. It is the ability to distinguish between a viral etiology that needs supportive care and a bacterial co-infection that actually requires targeted antimicrobials. That matters for stewardship. Using antibiotics based on a hunch versus using them based on a confirmed bacterial presence changes the resistance landscape in your clinic and the surrounding community.
Gastrointestinal panels work similarly but with a different pathogen menu. Giardia, Tritrichomonas, Clostridium, Parvovirus, Coronavirus, and a few others depending on the version. A common mistake I see is ordering the GI panel when a simple fecal exam would have caught the Giardia cysts just fine. The molecular test is more sensitive, yes, but it is also more expensive and you need to justify the cost. If you have a classic presentation with motile trichomonads on a wet mount, you can treat empirically. Save the PCR for the cases where the fecal exam is negative but the clinical suspicion remains high. Tick-borne disease testing through Zoetis Dx covers pathogens like Ehrlichia, Anaplasma, and Rickettsia in addition to some regional variants. This is useful in endemic areas where a tick bite alone does not tell you whether transmission occurred. A dog in North Carolina presenting with lameness and fever might have Lyme, but it might also have Ehrlichia or Anaplasma, and those require different antibiotics and different prognoses. The molecular test picks up the organisms directly rather than relying on antibodies, which means you catch active infection sooner than you would with serology alone. Antibody tests stay positive for months or years after an infection clears, so they cannot distinguish past exposure from current disease. PCR does not have that problem, though it can miss infections in the very early window before organisms reach detectable levels in the sample type you are using. There are real limitations to this technology that nobody likes to talk about in the marketing materials. False positives are possible, especially when you are running low-cycle thresholds near the detection limit. I once had a dog test weakly positive for a respiratory pathogen that was completely asymptomatic. The owner was convinced the dog was sick because of the result. We monitored it for two weeks without treatment, and it never showed any signs. That weak positive was likely residual genetic material from a resolved infection, not active disease. Always consider the cycle threshold value if your instrument provides it. A Ct below 35 is generally considered a strong positive. Between 35 and 40 is indeterminate and should be interpreted with clinical correlation. Above 40 is usually background noise.
Get the Full Details
False negatives happen too. If you swab a dog with upper respiratory disease but the viral load has already moved down into the lungs, a nasopharyngeal swab might come back negative even though the dog is actively infected. Sample collection technique matters enormously. A shallow nasal wipe is not the same as a proper nasopharyngeal swab that reaches behind the soft palate. I have seen technicians rush through sample collection because they were backed up in the exam room, and then blame the test when the result does not match the clinical picture. The test was fine. The sample was the problem. Retrain your staff on collection technique regularly. It is the single biggest source of pre-analytical error in my experience. Another nuance that comes up rarely but causes confusion is shedding versus infection. A dog recovering from Parvovirus can shed viral particles in its feces for weeks after clinical resolution. A PCR will detect that shedding and return a positive result even though the dog is no longer ill and no longer contagious in any meaningful sense. Telling a worried owner that their dog still tests positive for Parvo three weeks after recovery can cause unnecessary panic. Having a conversation about what the test actually means, and when a follow-up test might be warranted, goes a long way toward maintaining trust. Cost is the elephant in the room. A single Zoetis Dx panel runs significantly more than a traditional culture or rapid antigen test. Depending on your volume and your contract with Zoetis, a respiratory panel can cost anywhere from $80 to $150 per test at the client level, and more on the laboratory side. That is not cheap. It is worth it in the right case. It is not worth it when a cheaper test would have answered the question just as well. Use your clinical judgment. If the presentation is classic and the outcome would not change based on the result, do not order the expensive test just because you can. Order it when the result will change management.
For clinics that want to adopt this technology, the setup is relatively painless. You need the instrument, which Zoetis provides, along with the reagent cartridges and a dedicated bench space. The instrument requires minimal maintenance beyond routine calibration and quality control runs. Training takes about half a day for a small team to get comfortable with sample processing and result interpretation. Ongoing costs are primarily the reagent cartridges, which you order through your Zoetis representative or their online portal. Turnaround depends on whether you run tests in-house or send them out to a reference lab. In-house means same-day results for the client. Reference lab means you ship the sample and wait one to three business days. One operational detail that affects many practices is sample stability. Once you have collected the sample and mixed it with the lysis buffer, most Zoetis Dx samples are stable at room temperature for a defined period, usually 24 to 48 hours depending on the specific panel and buffer formulation. Check the package insert for your particular test. If you are sending samples out, shipping on ice is still the safest option, but it is not always required. Getting this wrong means degraded samples and invalid results, which brings us back to that dilution workaround I mentioned earlier. If a sample sits too long or gets exposed to temperature fluctuations, running it at a higher dilution can sometimes rescue it by reducing the concentration of degraded inhibitors. The broader impact on veterinary care is real but modest. Molecular diagnostics like Zoetis Dx do not replace the physical exam, the signalment, the history, or the basic laboratory work. They augment those tools by giving you information that was previously unavailable or took too long to obtain. In a practice that sees a high volume of respiratory or gastrointestinal cases, the ability to identify the causative agent quickly means faster targeted treatment, shorter hospitalization stays, and fewer empiric antibiotic prescriptions. Those are measurable improvements. They are not revolutionary. The technology is reliable once you understand its boundaries. Misuse leads to misdiagnosis. Proper use leads to better outcomes.
If you are considering implementing this in your clinic, start with one panel. Respiratory or gastrointestinal, depending on your caseload. Run it alongside your existing diagnostics for a few months and compare the results. Document how many cases changed management because of the molecular result versus how many came back positive but did not change the treatment plan. That data will tell you whether the investment pays off for your specific practice. Generic claims about next-generation diagnostics mean nothing without your own numbers. Track your own outcomes. That is what actually matters.
